We have previously demonstrated the existence of a melanoma tumor suppressor gene(s) on the long arm of chromosome 11 through suppression of tumorigenicity assays. Although loss of heterozygosity studies also support this ®nding, only a large critical region (44 cM) has been identi®ed to date on 11q22-25. To further localize a tumor suppressor gene(s) within this region, we have now generated and characterized nine melanoma microcell hybrids, each retaining an introduced fragment of 11q. Of the nine hybrids, four were suppressed for tumor formation in nude mice, while ®ve formed tumors at the same rate as the parental melanoma cell line (UACC 903). Molecular analysis of the hybrids with 118 microsatellite markers narrowed the location of a putative suppressor gene to a small (42 Mb) candidate region on 11q23 between the markers D11S1786 and D11S2077 and within the larger region frequently deleted in melanoma tumors and cell lines. While multiple tumor suppressor genes are likely to reside on 11q22-25, the presence of this region in all four suppressed hybrids supports the simplest model that a single locus is responsible for the suppressed phenotype observed in UACC 903.
Introduction
Cytogenetic and molecular evidence support the existence of tumor suppressor genes on chromosomes 1, 6, 9, 10, and 11 that are frequently targeted during the development of cutaneous malignant melanoma (Fountain, 1998) . Deletions or rearrangements of chromosome 11, which occur in 26 ± 58% of metastatic melanomas (Tomlinson et al., 1993 (Tomlinson et al., , 1996 Walker et al., 1995; Herbst et al., 1995) , are also frequently observed in other cancers, including those originating in the breast, ovary, lung, bladder, colon, and prostate (Keldysh et al., 1993; Foulkes et al., 1993; Hampton et al., 1994; Iizuka et al., 1995; Negrini et al., 1995; Tomlinson et al., 1995; Winqvist et al., 1995; Gudmundsson et al., 1995; Shaw et al., 1995; Gabra et al., 1996; Evans et al., 1996; Dahiya et al., 1997) . To date, loss of heterozygosity (LOH) studies on melanoma tumors have been relatively unsuccessful in identifying a con®ned region of loss on chromosome 11 (Herbst et al., 1995) and the most recent report suggests that multiple melanoma tumor suppressor genes may exist on this chromosome (Tomlinson et al., 1996) . Overall, these studies (as well as cytogenetic analyses; Thompson et al., 1995) indicate that one or more melanoma tumor suppressor genes reside on 11q22-25. Our own (unpublished) LOH analyses, performed on 90 melanoma tumors and cell lines, have also revealed frequent and extensive loss of a region distal to the 11q22.3-q23.1 marker D11S2000 (Goldberg et al., in preparation). The size of the consensus critical region (44 cM); from NCAM to D11S969) suggests that standard positional cloning approaches may not be successful in rapidly localizing a melanoma tumor suppressor gene(s) on 11q.
We have previously demonstrated that chromosome 11 is capable of suppressing the growth properties of two melanoma cell lines, MelJuSo and UACC 903. The introduction of an additional copy of chromosome 11 into MelJuSo dramatically decreased the ability of these cells to proliferate in vitro, while, in UACC 903, suppression of tumor formation was observed in nude mice (Robertson et al., 1996) . The locus responsible for these eects was localized to 11q. We also noted that this gene appeared to behave in a dosage-dependent manner and that loss or inactivation of only one copy (haploinsuciency) may be sucient during the development of melanoma. If so, homozygous deletions of this gene may not occur at a high frequency, potentially limiting the success of localizing this gene by positional means. We have, therefore, adopted a combined positional and functional approach to identify one or more melanoma tumor suppressor gene(s) on 11q.
In the current study, dierent subchromosomal fragments of 11q (Robertson et al., 1997) were introduced into the melanoma cell line UACC 903. A total of nine hybrids, four of which were suppressed for tumor formation in nude mice and ®ve of which were not, were characterized with closely-spaced microsatellite markers to determine what region(s) of 11q had been introduced and were correlated with the suppressed phenotype. The results of these analyses enabled us to eliminate most of 11q from involvement and narrow the location of a melanoma tumor suppressor gene to a small (42 Mb) critical region on 11q23.
Results

Subchromosomal fragments of 11q suppress tumor formation of UACC 903
Fragments of 11q were introduced into the melanoma cell line UACC 903 using microcell-mediated chromosome transfer (MMCT) techniques. UACC 903 cells respond in a measurable way to a tumor suppressor(s) on chromosome 11 (Robertson et al., 1996) ; also, molecular analysis (described below) revealed a large region of hemizygous loss on 11q in this cell line. The fragment donors for these transfers were selected from a panel of 25 mouse cell lines that contain distinct neomycin-selectable fragments of human chromosome 11 (Robertson et al., 1997) . Four donors (1.S2, E8, 10, and 7) with fragments of various sizes were chosen to assist in the identi®cation of a subregion on 11q that contained a suppressor gene.
Nine melanoma hybrids containing introduced fragments of 11q were characterized cytogenetically to determine that they retained an additional piece of 11q and to assess the stability of the fragment (Table 1) . In all cases, the introduced fragment was retained at a high frequency in the hybrid cell populations. In ®ve hybrids, these fragments were grossly intact, while the remaining four hybrids contained fragments that had undergone deletion during transfer. These deleted fragments, however, were stable; no additional rearrangements were observed during cell passaging. Although UACC 903 cells are aneuploid, all but one hybrid had a karyotype consistent with that of the parental melanoma cells, diering by only the presence of the transferred chromosome 11 fragment. The exception (E8/14) retained an additional copy of chromosome 5 which was not expected to alter the suppressed phenotype (Fountain, 1998; Thompson et al., 1995) .
Melanoma hybrid cells were injected into nude mice to determine if the 11q fragment present in each hybrid could suppress tumor formation. Four hybrids (1.S2/2, 1.S2/6, E8/10, and 7/1) exhibited levels of suppression equivalent to that observed when an intact copy of chromosome 11 was introduced into UACC 903 (19), while the other ®ve hybrids (1.S2/8, E8/14, E8/21, E8/ 42, and 10/1) formed tumors at rates equivalent to the parental UACC 903 cells (Figure 1 ).
Microsatellite marker analyses de®ne a candidate suppressor region
The nine melanoma hybrids were screened with 118 microsatellite markers to determine what region(s) of 11q was transferred into each one. Most of the markers were located within the previously de®ned 44 cM critical region on 11q22-25 frequently deleted in melanoma tumors (4, 5, Goldberg et al., in preparation) . Of the 118 markers, 80 were informative and 89.4 a Physical sizes of chromosome fragments were estimated from photographs of G-banded metaphase spreads. For each photograph a standard curve was constructed correlating the lengths of unaltered endogenous chromosomes found within each hybrid with the approximate physical size of each chromosome (Morton, 1991) . Sizes of chromosome fragments were interpolated from the standard curve. Estimates from three independent metaphase spreads were used to determine the standard curve. used to monitor the presence or absence of a donor allele in each hybrid ( Figure 2 ). Some non-informative markers were also valuable for establishing that a particular marker was absent from a donor fragment prior to its introduction into UACC 903 or could be tentatively evaluated based on dosage dierences between alleles in the hybrids versus endogenous alleles present in UACC 903 (data not shown). During the course of these studies, we also determined that the UACC 903 parental cell line had suered a loss from 11q22.3-qter since the genotypes at all markers (n=72) distal to D11S2000 were homozygous. The probability of observing this many homozygous genotypes, given that UACC 903 retained two copies of chromosome 11 and the heterozygosity values of the markers in this region are approximately 0.70, is astronomically small (0.30 72 or 2.25610
738
). The region(s) of 11q introduced into each of the nine hybrids and deleted in UACC 903 are shown in Figure 3 .
We identi®ed a single candidate suppressor region (CSR) that was (a) present in all four suppressed hybrids (shaded region; Figure 3 ), (b) located within the region of deletion in UACC 903 (bent arrow, Figure 3 ), and (c) inside the critical region de®ned by LOH studies (black bar; Figure 3 ). This region is anked by the markers D11S1786 and D11S2077 on 11q23 and is 42 Mb in size (Baysal et al., 1997, unpublished results) . While this region was also present in one non-suppressed hybrid (10/1), we presumed that deletion or mutation of the putative tumor suppressor gene had occurred in this hybrid. Four other putative CSRs (dashed boxes; Figure 3 ) were also identi®ed which were present in three of the four suppressed hybrids and absent in four or more of the nonsuppressed hybrids. While three of these regions contained or were subsequently determined to map immediately adjacent to a known candidate tumor suppressor locus (i.e., the multiple endocrine neoplasia 1 (MEN1), ataxia telangiectasia (ATM1), and DNAdamage checkpoint control (CHK1) genes), none of them (either the regions or the speci®c genes) were present on the donor fragment introduced into the 7/1 suppressed hybrid. Notably, the 7/1 hybrid, which retained the smallest donor 11q fragment, exhibited the same (or a slightly higher) level of suppression in nude mice when compared to the other three suppressed hybrids (Figure 1 ). The simplest model consistent with these data is that one gene is responsible for the suppressed phenotype and that this gene is located on the 11q fragment introduced into 7/1. This fragment is only 19 ± 27 Mb in size (estimates based on physical maps; Baysal et al., 1997; James et al., 1994; Arai et al., 1996) and consists of a 16 ± 19 Mb region around the centromere, a 0 ± 4 Mb region surrounding the neo selectable marker on 11q14, and a 3 ± 4 Mb region spanning the CSR, bordered by the markers D11S560 (most distal marker in MG7) and D11S4092 (Figure 3 ).
FISH analysis con®rms deletion of candidate suppressor region in UACC 903
FISH analysis was performed using a PAC (pDJ149k2) which mapped within the CSR to con®rm that only one copy of this region was present in UACC 903. This PAC has been completely sequenced and was determined by homology searches within the htgs database (http://www.ncbi.nlm.nih.gov/BLAST/) to contain the non-informative marker D11S1792 (located between the markers D11S938 and 17e5/GAAA), as well as most of the promyelocytic leukemia zinc ®nger (PLZF; Chen et al., 1993) locus (Figure 3) . A single hybridization signal was observed for this PAC in 20/20 metaphase spreads examined on UACC 903 (data not shown). This PAC hybridized to an undesignated marker chromosome previously determined to contain material from chromosome 11 by chromosome painting studies (Robertson et al., 1996) . This analysis conclusively demonstrated that UACC 903 had suered a loss of 11q material that included the CSR.
Microsatellite marker analyses on tumors from nude mice
Microsatellite markers were also used to monitor the retention of donor fragments in four tumors available on two (1.S2/2 and E8/10) of the suppressed hybrids. Only tumors from the E8/10 hybrid (TC#3L and TC#4L) exhibited losses of portions of the donor fragment, while those from the 1.S2/2 hybrid (TC#4R and TC#2R) appeared intact (data not shown). The deletions detected in the tumors from the E8/10 hybrid were both identical and targeted two non-contiguous regions on the donor fragment. One deletion extended proximally from D11S527 and the other extended (7) sign, respectively, above or below each panel. Mouse DNA, as well as DNAs isolated from the mouse donor hybrid retaining an intact human chromosome 11 (Hdm-18; Lugo et al., 1987) and the reduced chromosome 11 donors, served as controls along with the parental melanoma cell line (UACC 903). The D11S1327 result demonstrates introduction of this region into all four of the suppressed hybrids (1.S2/2, 1.S2/6, E8/10, and 7/1), as well as one of the non-suppressed hybrids (10/1). The marker D11S4092, which resides distal to D11S1327, was, by contrast, present in only the E8/10 and 10/1 hybrids. Notably, transfer of an allele from the 11q fragment present in the donor mouse hybrids into the melanoma hybrids was not always observed. For example, only E8/10, and not E8/21, E8/14, or E8/42, was positive for donor alleles at D11S1327 and D11S4092. The discovery of homozygous genotypes at these two markers in UACC 903 assisted in identifying a loss of 11q22-25 material in this melanoma cell line 11q23 melanoma tumor suppressor gene GP Robertson et al Figure 3 Retention of chromosome 11 fragments in nine melanoma hybrids and identi®cation of an 11q22-25 deletion in UACC 903. Eighty-three chromosome 11 markers (some in marker groups (MG1-15)) and 16 genes (underlined, including the neo selectable marker) are listed from pter to qter (Vanagaite et al., 1995; Dib et al., 1996; Baysal et al., 1997; James et al., 1994; Arai et al., 1996; Li et al., 1997; Kawana et al., 1997; Manickam et al., 1997; unpublished results) ; designations for hybrids and UACC 903 (903) are provided at the top. The approximate location of a number of genes/markers is indicated to the left on an ideogram of chromosome 11. The location of the recently identi®ed CHK1 DNA-damage checkpoint control gene (Sanchez et al., 1997) was based on mapping analyses performed on YACs from the 11q24 region (EKG and JWF, unpublished results). A black/white circle indicates the presence/absence, respectively, of a donor chromosome 11 allele in the hybrids, while non-polymorphic loci and inconclusive results are indicated as light gray circles or blank spaces, respectively. In the case of UACC 903 (903), a white circle indicates the retention of two alleles (or a heterozygous genotype), while a cross-hatched circle indicates a homozygous genotype. The location of the neo marker on the donor fragments (checkered circles) was assumed due to the presence of this region in all nine of the hybrids. This was based primarily on the universal retention of one marker, AFM289YC3, which, though technically noninformative (i.e., the donor allele was the same as one of the two endogenous alleles in UACC 903), revealed a convincing 2 : 1 dosage dierence between alleles present in the hybrids versus those present in UACC 903 (dark gray circles). The presence or absence of a donor copy of the centromere marker D11Z1 was determined by FISH. Markers with identical genotypes in the hybrids were grouped together; the total number of markers in each group is indicated in parentheses. Markers groups are as follows: MG1=D11S1338, D11S921, and D11S1310; MG2=D11S907 and D11S935; MG3=D11S1357, D11S1298, and D11S956; MG4=D11S876, D11S900, D11S35, D11S898, and D11S1782; MG5=D11S1343, D11S1787, and D11S1819; MG6=D11S1391, D11S897, D11S4192, and D11S4090; MG7=D11S3179, and D11S560; MG8=D11S29 and D11S1356; MG9=D11S614 and D11S1364; MG10=D11S1299, D11S528, D11S1345, D11S1336, D11S1353, D11S836, D11S964, D11S1316, and D11S1284; MG11=D11S933, D11S689. D11S2090, and AFM210VE3; MG12=D11S1894, D11S975, D11S990, D11S1896; MG13=D11S934 11q23 melanoma tumor suppressor gene GP Robertson et al distally from D11S2000 (see Figure 3 for marker locations). The distal loss directly mimics the endogenous deletion observed on 11q in the parental cell line UACC 903 and further supports the placement of the tumor suppressor within this region. The proximal region of loss overlaps another potential CSR located between the loci D11S527 and MEN1. This region, however, was not present on the fragment in the 7/1 hybrid and does not appear to be deleted in UACC 903 (Figure 3 ), making it a less likely location for the tumor suppressor gene.
Discussion
This study represents an extended eort to localize a tumor suppressor gene(s) on 11q. While deletions of 11q22-25 have been reported in a broad variety of cancers, including those originating in the breast, ovary, lung, bladder, and prostate (Keldysh et al., 1993; Foulkes et al., 1993; Hampton et al., 1994; Iizuka et al., 1995; Negrini et al., 1995; Tomlinson et al., 1995; Winqvist et al., 1995; Gudmundsson et al., 1995; Shaw et al., 1995; Gabra et al., 1996; Evans et al., 1996; Dahiya et al., 1997) , as well as from nevi (Tomlinson et al., 1993 (Tomlinson et al., , 1996 Walker et al., 1995; Herbst et al., 1995) , molecular studies have generally failed to identify a consistent critical region and have led to the conclusion that multiple tumor suppressor genes probably exist within this region. De®ning the location of these putative genes by solely positional means has been problematic, even to the extent that independent LOH studies performed on the same tumor type (e.g., breast cancer) have not yielded consistent results or been successful in pinpointing the exact location of a tumor suppressor gene (Hampton et al., 1994 ; Iizuka et al., 1995; Negrini et al., 1995; Tomlinson et al., 1995; Winqvist et al., 1995; Gudmundsson et al., 1995) . Molecular ®ndings on melanoma are no exception, where 26 ± 58% of metastatic melanomas have been determined to harbor predominantly large (544 cM) deletions on 11q22-25 (Tomlinson et al., 1993 (Tomlinson et al., , 1996 Walker et al., 1995; Herbst et al., 1995, unpublished results) . The functional analyses described in this report have been successful in rapidly narrowing the location of a melanoma tumor suppressor gene to a 42 Mb region on 11q23 between the markers D11S1786 and D11S2077. This localization was based primarily on the fact that this small region of 11q23 had been introduced into all four of our suppressed melanoma hybrids. These hybrids, as well as ®ve non-suppressed hybrids, were characterized in detail with 118 microsatellite markers, 65 of which were located at average intervals of 200 ± 450 kb (Baysal et al., 1997; James et al., 1994; Arai et al., 1996) within the 11q22-25 region commonly deleted (from D11S2000 to D11S969) in melanoma tumors and cell lines. Analyses with these markers identi®ed only one region that was retained in the suppressed hybrids, deleted in our parental melanoma cell line UACC 903, and located within the critical region de®ned for melanoma tumors and cell lines.
The CSR identi®ed in this study has previously been shown to be the site of a familial predisposition locus for nonchroman paragangliomas (PGL1; Baysal et al., 1997) and is also the location of a tumor suppressor gene targeted in non-small cell lung cancer (NSCLC; Iizuka et al., 1995; Murakami et al., 1998) . The critical region de®ned by genetic linkage analysis for PGL1 maps between the markers D11S938 and D11S1885 (the latter marker maps just proximal to D11S2077; see Figure 3 ) which is contained in its entirety within our CSR (Baysal et al., 1997) . Similarly, the region recently narrowed by suppression of tumorigenicity assays for NSCLC includes D11S1885 and extends through the marker D11S4111 (Murakami et al., 1998) . The fact that our CSR directly overlaps these two other candidate regions, both of which are also 42 Mb, provides even greater con®dence that the conclusions drawn from the current study are valid and that the presence of this small region in all four of our suppressed hybrids is not coincidental. The consensus critical region identi®ed by these three independent studies lies within a small region of approximately 100 kb (Murakami et al., 1998) , just proximal to D11S1885.
There are a number of noted similarities between the ®ndings described in the current study and those recently reported by Murakami et al. (1998) who introduced YACs from this candidate region into a human NSCLC cell line. In both instances, the parental NSCLC and melanoma cell lines (A459 and UACC 903, respectively) harbored losses of 11q, formed tumors in nude mice at approximately equivalent rates (14 ± 16 days), and were suppressed to the same extent by the candidate region (latency periods of 28 ± 42 days). In our own case, this equivalent' level of suppression was observed even in and D11S4151; MG14=D11S1884 and D11S910; and MG15=D11S4125 and D11S4098. A heterozygous designation for MG1 ± 4 (white circles) in UACC 903 was based on the identi®cation of one or more heterozygous genotype(s) in each group; all markers present in MG5 ± 15 were homozygous (cross-hatched circles) in UACC 903. The following markers (from pter to qter) were determined to be non-informative in the hybrids and were excluded from the ®gure: D11S988, D11S1334, D11S1335, D11S1765, D11S480, D11S1883, D11S1783, D11S913, D11S1889, D11S4155, D11S534, D11S901, D11S1354, D11S931, D11S1358, D11S917, D11S920, D11S1339, D11S4161, D11S1886, D11S1325, D11S2003, D11S2105, D11S1347, D11S3178, D11S4078, D11S1792, D11S1885, D11S4145, D11S1340, D11S939, D11S924, D11S925, D11S1328, D11S4158, and D11S430. An exception was made for the marker D11S1786 which was determined to be absent from the donor 1.S2 fragment introduced into a subset of the hybrids (1.S2/2, 1.S2/8, and 1.S2/6) and served to mark the proximal boundary of the candidate suppressor region (CSR). Regions retained in suppressed (cross-hatched vertical boxes) and non-suppressed (open vertical boxes) hybrids are delineated. The CSR (gray shaded region) was identi®ed as the only region that was retained in all four suppressed hybrids, located within the critical region frequently deleted in melanoma tumors and cell lines (vertical black bar; Herbst et al., 1995; Tomlinson et al., 1996, unpublished results) , and present within the region speci®cally deleted in UACC 903 (bent arrow, boxed region). The markers immediatelȳ anking the CSR, as well as the approximate size (in megabases) of the region, are indicated to the right. Four other regions (dashed boxes) were also present in three out of four of the suppressed hybrids and 41 of the ®ve non-suppressed hybrids. None of these regions nor the candidate genes within or near them (i.e., MEN1, ATM and CHK1), however, had been introduced into the 7/ 1 suppressed hybrid (as indicated by white circles) complex hybrids where additional fragments of chromosome 11 (containing other potential candidate loci) had been introduced. The hybrid 7/1 provided the most convincing evidence for the localization of a critical gene since the introduced 11q fragment in this cell line consisted primarily of a 3 ± 4 Mb region immediately surrounding the common CSR identi®ed in both studies. The concordance between these two independent results, obtained by distinct techniques in dierent types of cancer cells, is highly encouraging.
The fact that our three other suppressed hybrids (which contained transferred fragments covering most of 11q) exhibited levels of suppression similar to 7/1 suggests that no other 11q tumor suppressor genes contributed to any great extent to the suppressed phenotype observed in UACC 903. Speci®cally, these results diminish the possibility that either the ATM or CHK1 genes are targets in melanoma development and refute the potential involvement of CHK1 in cancer (Sanchez et al., 1997) . The latter conclusion is also supported by ®ndings of Sanchez et al. (1997) who did not observe any perturbation of the cell cycle when they introduced this DNA-damage checkpoint control gene into cervical carcinoma (HeLa) cells. Notably, an 11q gene(s) responsible for tumor suppression in HeLa cells has previously been shown to reside proximal to CHK1 within a region that directly overlaps the CSR identi®ed in this study (Saxon et al., 1986) .
The critical region containing the CSR is now small enough (100 kb) to examine by gene transfer methods. A PAC covering this region has been isolated which contains 9 potential candidate loci, including a large gene of currently unknown function that extends throughout the entire PAC (E Goldberg, P Pollock, J Welch, N Hayward, and J Fountain, unpublished results). Our part in localizing this critical region by functional means was eective and, importantly, did not require the generation or analysis of large numbers of hybrid cell lines. Even though most of the 11q fragments transferred into UACC 903 were not small, the recovery of additional deletions increased our overall eciency in narrowing this region. We were also able to convincingly distinguish suppressor activity in melanoma hybrids that retained dierent fragments of various sizes despite potential gene dosage eects and/or the possibility that more than one 11q tumor suppressor might contribute to the suppressed phenotype. Our results, like those of Murakama et al. (1998) , who utilized a dierent type of genomic fragment for transfer, emphasizes the increasing importance of functional analyses in pinpointing the location of tumor suppressor genes. This approach has the potential to be of more general use for the localization of suppressor loci in the future, especially where evidence of genetic linkage or homozygous chromosome deletions does not exist and where gene dosage eects suggest Knudson's two-hit model (Knudson, 1971) may not apply.
Materials and methods
Cell culture and chromosome transfer
Cell lines were grown in DMEM supplemented with 5% fetal calf serum (Gemini Bioproducts, Calabasas, CA, USA) in a humidi®ed 5% CO 2 atmosphere at 378C. Medium for hybrid lines was further supplemented with 500 mg/ml Geneticin (BRL). The human melanoma cell line UACC 903 was obtained from Dr Jerey Trent (National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, USA). The microcell-mediated transfer of chromosome fragments was carried out as previously described (Killary et al., 1995) .
Chromosome analysis
Human chromosomes were identi®ed in metaphase chromosome spreads that were G-banded according to standard protocols (Barch, 1991) . Fluorescence in situ hybridization (FISH) to interphase nuclei and metaphase spreads was carried out as described in Trask and Pinkel (1990) . Biotinylated probes for the centromere of chromosome 11 (D11Z1), as well as the 11q23 locus D11S1792 (PAC pDJ149k2; purchased from Genome Systems, Inc.), were prepared as described in Robertson et al. (1997) . The identity of the PAC was con®rmed by PCR ampli®cation with primers speci®c for the marker D11S1792.
Tumorigenicity assays
Formation of tumors was measured in immunode®cient Balb/c (nu/nu) mice (Robertson et al., 1996) . Cells were injected subcutaneously into the¯anks of 4-to 6-week-old male mice. In each of two separate experiments at least 3 ± 4 mice received an injection in both the right and left¯anks, so a minimum of 12 ± 16 injection sites (5610 6 cells/injection) were observed per cell line. Animals were examined at 7-day intervals for 1 ± 2 months. The dimensions of developing tumors were measured with a millimeter ruler, and the sizes were estimated in units of cubic millimeters. In general, one or more tumors from each hybrid cell line were harvested aseptically (after animals were euthanized) for the reestablishment of in vitro cultures and extraction of DNA.
Microsatellite marker analysis
Primers for microsatellite marker assays were purchased through Research Genetics or synthesized (Gibco; BRL) from information available through published reports (Vanagaite et al., 1995; Dib et al., 1996; Baysal et al., 1997) or the Genome Database (http://gdbwww.gdb.org/gdb). Multiplex reactions were generally performed with two sets of primers at a time. Reactions were performed according to the manufacturer (Research Genetics) with 25 ± 200 ng of template in the presence of 1.0 mCi of [a-32 P]dCTP using the following PCR ampli®cation conditions: initial denaturation at 948C for 3 min; 948C 30 s, 608C 30 s, 728C 30 s (4 cycles); 948C 30 s, 568C 30 s, 728C 30 s (26 cycles); ®nal extension at 728C for 5 min. Labeled products were separated on 6% denaturing polyacrylamide (Sequagel; National Diagnostics) gels and run either at 5 W overnight or 120 W for 3 ± 5 h at room temperature. Gels were dried and exposed to ®lm for 2 ± 16 h. Results from all markers were scored independently by two individuals (EKG and JWF); critical or ambiguous ®ndings were veri®ed in repeat assays.
Gene analysis
Primers designed to amplify exons 1 (F-5'GGGGCC-TTGTTTGGCTGATT3'; R-5'CTGTGGGGAGACTATGG-TAA3') and 37 (F-5'CTGTTCACCTCACTGAAACC3'; R-5'GCAGAGATGTTCCTTAAGACC3') of the human ATM gene , the 3' UTR of CHK1 (F-5'CTGGGGAATCCTGGTGAATA3'; R-5'GGAAAACT-CATGATCCCCTGA3') (Sanchez et al., 1997 ; Genbank accession number AF016582), and exon 1 (F-5'ATTTTC-CAGAAGGCACTGCG; R-5'AGCCTGCTGGGACATGA-AGT) of MEN1 ; Genbank accession numbers U93236 and U93237) were used to determine if these genes were present on any of the fragments of 11q prior to introduction into the melanoma hybrids. DNAs isolated from the donor hybrids (1.S2, E8, 10, and 7) and mouse A9 cells served as templates and conditions for PCR and gel electrophoresis were the same as those employed for the microsatellite markers or were performed in the absence of 32 P-labeled dCTP, followed by visualization on 1.5% agarose gels. Results were con®rmed in duplicate assays.
Note added in proof
Recently, another 11q23 candidate tumor suppressor gene was identi®ed on 11q23 (Wang et al., 1998) . This gene, PPP2R1B, encodes a subunit of the protein phosphatase 2A and has been shown to be mutated at a low frequency (15%) in lung and colon tumors. We have determined that PPP2R1B is not responsible for the suppression observed in our melanoma hybrids. Speci®cally, this gene maps within MG6 proximal to our CSR (Figure 3 ) and has been determined (by Southern analysis) to not reside on the 11q fragments introduced into the suppressed hybrids 1.S2/2, 1.S2/6 and 7/1.
